Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.

Cancer treatment reviews - 1 Apr 2016

Yang Sherry X, Polley Eric, Lipkowitz Stanley

Abstract excerpt

PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations and AKT activation by phosphorylation (pAKT) are often detected in many cancers and especially at high frequencies in breast cancer. Mounting data suggest that PIK3CA mutations or pAKT are mostly associated with better or insignificant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Oncogene Protein v-akt

Share to Paclitaxel

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 26995633
DOI: 10.1016/j.ctrv.2016.03.004
PMCID: PMC7436195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.PMID 26995633Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical StudiesSemantic proximity Read ↗

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Semantic proximity Read ↗

HER2/PI3K/AKT pathway in HER2-positive breast cancer: A reviewSemantic proximity Read ↗

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast CancerSemantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

Clinicopathogenomic analysis of AKT1-PIK3CA-PTEN-altered luminal metastatic breast cancer in JapanSemantic proximity Read ↗

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitorsSemantic proximity Read ↗

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.Semantic proximity Read ↗

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.Semantic proximity Read ↗

Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.